All In Biotech

Drug Trial Radar · NCT03032510

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections

A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections

Last checked: Nov 20, 2026Latest source record: Jan 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,205 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,205

Actual

Start

Jan 2017

Primary completion

Dec 2017

Study completion Jan 2018

Sponsor

Sponsor type
Industry
First posted
Jan 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).

Conditions

  • Complicated Urinary Tract Infections

Interventions

  • EravacyclineDrug

  • ErtapenemDrug

  • PlaceboDrug

  • LevofloxacinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the EOI VisitTime frame: End of Infusion
  2. Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure (TOC) VisitTime frame: TOC visit (14-17 days after randomization)

Locations

69 sites in 12 countries. Site status is shown where the registry gives one.

  • Site not named

    Fullerton, California

  • Site not named

    Los Angeles, California

  • Site not named

    Torrance, California

  • Site not named

    Coral Gables, Florida

  • Site not named

    Doral, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Columbus, Georgia

  • Site not named

    St Louis, Missouri

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Baytown, Texas

  • Site not named

    Graz, Austria

  • Site not named

    Linz, Austria

  • Site not named

    Salzburg, Austria

  • Site not named

    Pleven, Bulgaria

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Razgrad, Bulgaria

  • Site not named

    Rousse, Bulgaria

  • Site not named

    Smyadovo, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Varna, Bulgaria

  • Site not named

    Veliko Tarnovo, Bulgaria

  • Site not named

    Tallinn, Estonia

  • Site not named

    Tartu, Estonia

  • Site not named

    Võru, Estonia

  • Site not named

    K'ut'aisi, Georgia

  • Site not named

    Tbilisi, Georgia

  • Site not named

    Baja, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Miskolc, Hungary

  • Site not named

    Nagykanizsa, Hungary

  • Site not named

    Nyíregyháza, Hungary

  • Site not named

    Sopron, Hungary

  • Site not named

    Szentes, Hungary

  • Site not named

    Tatabánya, Hungary

  • Site not named

    Jelgava, Latvia

  • Site not named

    Riga, Latvia

  • Site not named

    Valmiera, Latvia

  • Site not named

    Chisinau, Moldova

  • Site not named

    Brasov, Romania

  • Site not named

    Bucharest, Romania

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.